Login / Signup

Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study.

Kristian B FilionAntonios DourosLaurent AzoulayHui YinOriana H YuSamy Suissa
Published in: British journal of clinical pharmacology (2019)
Initiating treatment of type 2 diabetes with a sulfonylurea rather than metformin is associated with higher rates of ischaemic stroke, cardiovascular death, and all-cause mortality.
Keyphrases
  • cardiovascular events
  • type diabetes
  • cardiovascular disease
  • coronary artery disease
  • insulin resistance
  • metabolic syndrome
  • combination therapy
  • skeletal muscle
  • adipose tissue